Novartis Pharma Stein AG (manufacturing, quality control, packaging, batch release)

The drug is indicated for monotherapy in adults and children aged 10 years and older with highly active relapsing-remitting multiple sclerosis. This applies to patients who have not responded to a previous course of treatment or those experiencing a rapidly progressive, severe course of the disease.

Dosage form: capsules, hard

ATC: L04AA27